Iqvia (IQV) Receives New Coverage from Analysts at Evercore ISI

Evercore ISI started coverage on shares of Iqvia (NYSE:IQV) in a research note published on Thursday, MarketBeat Ratings reports. The firm issued an outperform rating and a $112.00 price target on the medical research company’s stock.

IQV has been the subject of several other reports. KeyCorp reiterated a sector weight rating and set a $100.00 price objective on shares of Iqvia in a research note on Friday, November 10th. Credit Suisse Group reissued an outperform rating and set a $110.00 target price (up from $98.00) on shares of Iqvia in a research report on Monday, October 16th. Zacks Investment Research raised shares of Iqvia from a hold rating to a buy rating and set a $107.00 target price on the stock in a research report on Wednesday, October 11th. Mizuho cut shares of Iqvia from a buy rating to a neutral rating and set a $90.00 target price on the stock. in a research report on Thursday, November 9th. Finally, TheStreet raised shares of Iqvia from a c+ rating to a b rating in a research report on Wednesday, December 13th. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $107.79.

Iqvia (IQV) traded up $3.08 on Thursday, reaching $103.00. 1,323,906 shares of the company’s stock traded hands, compared to its average volume of 908,159. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia has a 12 month low of $74.80 and a 12 month high of $110.67. The stock has a market capitalization of $21,422.77, a P/E ratio of 355.18, a P/E/G ratio of 1.42 and a beta of 0.61.

Iqvia (NYSE:IQV) last released its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.05. Iqvia had a net margin of 0.58% and a return on equity of 12.60%. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the previous year, the firm earned $1.00 earnings per share. Iqvia’s revenue for the quarter was up 77.6% on a year-over-year basis. equities research analysts anticipate that Iqvia will post 4.62 EPS for the current year.

In related news, insider Ari Bousbib sold 46,080 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $108.14, for a total value of $4,983,091.20. Following the sale, the insider now directly owns 1,036,839 shares of the company’s stock, valued at $112,123,769.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Connaughton sold 1,163,191 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total transaction of $118,645,482.00. The disclosure for this sale can be found here. Insiders sold 8,806,558 shares of company stock worth $898,716,708 over the last ninety days. 6.40% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Winslow Evans & Crocker Inc. acquired a new stake in Iqvia in the fourth quarter valued at $123,000. Tillar Wenstrup Advisors LLC acquired a new stake in Iqvia in the fourth quarter valued at $1,995,000. State of Alaska Department of Revenue acquired a new stake in Iqvia in the fourth quarter valued at $2,932,000. Oakbrook Investments LLC acquired a new stake in Iqvia in the fourth quarter valued at $652,000. Finally, Fox Run Management L.L.C. acquired a new stake in Iqvia in the fourth quarter valued at $250,000. 95.78% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Iqvia (IQV) Receives New Coverage from Analysts at Evercore ISI” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.com-unik.info/2018/01/21/iqvia-iqv-receives-new-coverage-from-analysts-at-evercore-isi.html.

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit